PAI-1
- Product Name
- PAI-1
- Chemical Name
- PAI-1
- Synonyms
- PAI-1;ARMAPE;PAI-1, RAT;MOUSE PAI-1;PAI-1, MOUSE;PAI-1, HUMAN;PAI-1, MUTANT, MOUSE;PLASMINOGEN ACTIVATOR INHIBITOR 1;PLASMINOGEN ACTIVATOR INHIBITOR-1, RAT;MOUSE PLASMINOGEN ACTIVATOR INHIBITOR-1
- CBNumber
- CB1438644
- Molecular Formula
- C27H47N9O9S
- Formula Weight
- 673.78
- MOL File
- Mol file
N-Bromosuccinimide Price
- Product number
- 528205
- Product name
- Plasminogen Activator Inhibitor-1, Human, Recombinant
- Purity
- The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applicatio
- Packaging
- 50μg
- Price
- $390
- Updated
- 2024/03/01
- Product number
- 027470
- Product name
- Plasminogen Activator Inhibitor 1
- Packaging
- 96Tests
- Price
- $706
- Updated
- 2021/12/16
- Product number
- 156349
- Product name
- Plasminogen Activator Inhibitor 1
- Packaging
- 10ug
- Price
- $333
- Updated
- 2021/12/16
- Product number
- 027469
- Product name
- Plasminogen Activator Inhibitor 1
- Packaging
- 96Tests
- Price
- $851
- Updated
- 2021/12/16
- Product number
- P4256-38
- Product name
- Plasminogen Activator Inhibitor Type 1, Mouse Assay Kit, BioAssay™
- Packaging
- 1Kit
- Price
- $1042
- Updated
- 2021/12/16
PAI-1 Chemical Properties,Usage,Production
Enzyme inhibitor
This 402-residue serine protease inhibitor, or serpin (MW = 45074 g/mol; Abbreviation: PAI-1) binds to and inhibits plasminogen activators-tissuetype plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). This inhibition reduces plasmin production and suppresses dissolution of fibrin clots. Elevated PAI-1 levels correlate with an increased cardiovascular disease risk, a behavior that has also been linked to obesity and metabolic syndrome. Pharmacological suppression of PAI-1 is a likely way to prevent or treat vascular disease. Reduced PAI-1 levels may result in increased fibrinolysis and an associated bleeding diathesis. PAI-1 was initially identified in the 1980s, and the first reported case of PAI-1 deficiency appeared in 1989. Unambiguous proof that PAI-1 deficiency as a cause of a bleeding disorder has been rare, but use of selective PAI inhibitors (See PAI-749) may clarify this point. Because of lack of standardized commercially available PAI-1 activity assay sensitive in the lowest range, the true prevalence of this rare condition has yet to be established.
PAI-1 Preparation Products And Raw materials
Raw materials
Preparation Products
PAI-1 Suppliers
- Tel
- --
- Fax
- --
- export@ecochem.dk
- Country
- Europe
- ProdList
- 6371
- Advantage
- 66
- Tel
- --
- Fax
- --
- Sales@kemikalieimport.dk
- Country
- Europe
- ProdList
- 6685
- Advantage
- 47